Ser214

Site Information
sRsGLyRsPsMPENL SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 448417

In vivo Characterization
Methods used to characterize site in vivo:	2D analysis ( 19 ) , [32P] bio-synthetic labeling ( 19 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 ) , mutation of modification site ( 8 , 18 ) , peptide sequencing ( 19 ) , phospho-antibody ( 18 ) , phosphoamino acid analysis ( 19 ) , phosphopeptide mapping ( 19 ) , western blotting ( 8 )
Disease tissue studied:	breast cancer ( 5 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 5 ) , non-small cell lung cancer ( 5 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 7 ) , breast ( 1 ) , BT-20 (breast cell) ( 5 ) , BT-549 (breast cell) ( 5 ) , H2009 (pulmonary) ( 5 ) , H2887 (pulmonary) ( 5 ) , HCC1937 (breast cell) ( 5 ) , HCC2279 (pulmonary) ( 5 ) , HeLa (cervical) ( 2 , 4 , 6 , 8 , 10 , 18 ) , HOP62 (pulmonary) ( 5 ) , Jurkat (T lymphocyte) ( 3 , 9 , 11 , 13 , 14 ) , K562 (erythroid) ( 4 , 15 ) , MCF-7 (breast cell) ( 5 ) , MDA-MB-231 (breast cell) ( 5 ) , MDA-MB-468 (breast cell) ( 5 ) , MKN-45 (gastric) ( 12 ) , NCI-H1568 (pulmonary) ( 5 ) , NCI-H157 (pulmonary) ( 5 ) , NCI-H1666 (pulmonary) ( 5 ) , NCI-H2172 (pulmonary) ( 5 ) , NCI-H322 (pulmonary) ( 5 ) , NCI-H441 (pulmonary) ( 16 , 17 ) , NCI-H520 (squamous) ( 5 ) , NCI-H647 (pulmonary) ( 5 ) , PC9 (pulmonary) ( 5 ) , REF52 (fibroblast) ( 19 )

Upstream Regulation
Putative in vivo kinases:	CDK1 (human) ( 18 ) , CDK2 (human) ( 8 )
Kinases, in vitro:	CDK1 (human) ( 18 , 19 )

Downstream Regulation
Effects of modification on CDC25C:	enzymatic activity, induced ( 8 ) , molecular association, regulation ( 18 )
Effects of modification on biological processes:	cell adhesion, altered ( 19 ) , cell cycle regulation ( 18 , 19 )
Inhibit interaction with:	14-3-3 beta (human) ( 18 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
3	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
4	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
5	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
6	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
7	Guo A (2010) CST Curation Set: 9968; Year: 2010; Biosample/Treatment: cell line, 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
8	Bagheri-Yarmand R, et al. (2010) Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C. Cancer Res 70, 5085-95 20530684 Curated Info
9	Moritz A (2010) CST Curation Set: 8865; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
10	Zhou J (2009) CST Curation Set: 7615; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
11	Possemato A (2008) CST Curation Set: 5542; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
12	Moritz A (2008) CST Curation Set: 5379; Year: 2008; Biosample/Treatment: cell line, MKN-45/wortmannin; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS/T) Immunoaffinity Beads Cat#: 1979 Curated Info
13	Possemato A (2008) CST Curation Set: 3661; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:pSXXXpS Curated Info
14	Possemato A (2007) CST Curation Set: 2647; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
15	Possemato A (2007) CST Curation Set: 2633; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpSAntibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) Arg-X-Tyr/Phe-X-pSer Motif Antibody Cat#: 2981 Curated Info
16	Moritz A (2005) CST Curation Set: 784; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
17	Moritz A (2005) CST Curation Set: 785; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
18	Bulavin DV, et al. (2003) Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat Cell Biol 5, 545-51 12766774 Curated Info
19	Strausfeld U, et al. (1994) Activation of p34cdc2 protein kinase by microinjection of human cdc25C into mammalian cells. Requirement for prior phosphorylation of cdc25C by p34cdc2 on sites phosphorylated at mitosis. J Biol Chem 269, 5989-6000 8119945 Curated Info
20	Izumi T, Maller JL (1993) Elimination of cdc2 phosphorylation sites in the cdc25 phosphatase blocks initiation of M-phase. Mol Biol Cell 4, 1337-50 7513216 Curated Info